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Aim To assess the efficacy and effectiveness of seasonal 
influenza vaccines in healthy children up to the age of 18 
years.
Methods MedLine, EMBASE, CENTRAL, CINAHL, WHOLIS, 
LILACS, and Global Health were searched for randomized 
controlled trials and cohort and case-control studies inves-
tigating the efficacy or effectiveness of influenza vaccines 
in healthy children up to the age of 18 years. The studies 
were assessed for their quality and data on the outcomes 
of influenza-like illness, laboratory-confirmed influenza, 
and hospitalizations were extracted. Seven meta-analyses 
were performed for different vaccines and different study 
outcomes.
Results Vaccine efficacy for live vaccines, using random 
effects model, was as follows: (i) for similar antigen, using 
per-protocol analysis: 83.4% (78.3%-88.8%); (ii) for simi-
lar antigen, using intention to treat analysis: 82.5 (76.7%-
88.6%); (iii) for any antigen, using per protocol analysis: 
76.4% (68.7%-85.0%); (iv) for any antigen, using intention 
to treat analysis: 76.7% (68.8%-85.6%). Vaccine efficacy for 
inactivated vaccines, for similar antigen, using random ef-
fects model, was 67.3% (58.2%-77.9%). Vaccine effective-
ness against influenza-like illness for live vaccines, using 
random effects model, was 31.4% (24.8%-39.6%) and using 
fixed-effect model 44.3% (42.6%-45.9%). Vaccine effective-
ness against influenza-like illness for inactivated vaccines, 
using random effects model, was 32.5% (20.0%-52.9%) and 
using fixed-effect model 42.6% (38.3%-47.5%).
Conclusions Influenza vaccines showed high efficacy in 
children, particularly live vaccines. Effectiveness was lower 
and the data on hospitalizations were very limited.
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Influenza virus causes an acute respiratory tract infection, 
which results in considerable morbidity and mortality 
worldwide (1,2). Influenza A genus is classified into many 
different serotypes; H1N1 and H3N2 notably cause disease 
in humans. Population groups at particular risk of influ-
enza include children, pregnant women, the elderly, and 
patients with co-morbidities (3). Prevention of influenza is 
a major health issue worldwide, but providing protection 
by vaccination is challenging because each season the dis-
ease is caused by different strains of the virus. Current rec-
ommendations for influenza vaccination include people 
over the age of 65, pregnant women, people with chronic 
respiratory illness, and those in long-stay residential care 
homes (4). Influenza vaccines are not typically recom-
mended for use in healthy children. Vaccination of healthy 
children aged from 6 to 24 months has been advocated in 
the USA, since 2004, which has gradually included children 
up to 59 months, and the current recommendation is to 
vaccinate all children from 6 months up to 19 years – with 
particular emphasis on children under the age of 5 or with 
chronic illnesses (5). No influenza vaccines have been ap-
proved for use in children younger than 6 months (6).
There are two types of vaccine available – live and inacti-
vated, both of which can be used in children. They contain 
three different virus strains: two influenza A (H1N1-like and 
H3N2-like) and one influenza B, which have to be adminis-
tered annually. Live vaccines are administered via an intra-
nasal spray, whereas inactivated vaccines are injected, ei-
ther intramuscularly or intradermally. Inactivated influenza 
vaccines contain killed virus, which makes them safer for 
use in pregnant women and those with underlying medi-
cal conditions; they cannot induce mild signs and symp-
toms of influenza like live vaccines. Vaccines can be adju-
vanted to improve their immunogenicity (7). Inactivated 
influenza vaccines have been successfully adjuvanted and 
their safety and immunogenicity proven for use in children 
(8). It has also been hypothesized that vaccinating children 
against influenza has indirect benefits, such as reducing in-
fluenza-related morbidity and mortality in the elderly pop-
ulation (9). This study aimed to assess which vaccines were 
most appropriate for use in healthy children from 6 months 
to 18 years of age, by critically and systematically reviewing 
the evidence on their efficacy and effectiveness and per-
forming meta-analysis of the available information.
MetHoDS
Search of the literature
We aimed to identify all randomized control trials (RCTs) 
and cohort or case-control studies investigating the 
effectiveness or efficacy of influenza vaccines in reducing 
the incidence of influenza-like illness (ILI) or laboratory-
confirmed influenza in children. In order to achieve this we 
searched Ovid MEDLINE (In-Process & Other Non-Indexed 
Citations and Ovid MEDLINE 1946 to Present), Embase + 
Embase Classic (1947 to present), the Cochrane Central 
Register of Controlled Trials (CENTRAL), Cumulative Index 
of Nursing and Allied Health Literature (CINAHL), World 
Health Organisation Library Information System (WHOLIS), 
Latin American and Caribbean Health Sciences Literature 
(LILACS), and Global Health Library (1910 to December 
2011) using different combinations including the following 
search terms: influenza vaccines, attenuated vaccines, live 
vaccines, vaccination, human influenza, child, preschool-
child, infant, influenza-like illness, hospitalization.
After elimination of duplicates, results of searches from all 
databases combined identified 2105 potentially relevant 
articles. The titles and abstracts were screened and studies 
measuring only the safety or immunogenicity of vaccines 
were excluded, and so were the studies on pandemic in-
fluenza vaccines, studies assessing efficacy or effectiveness 
of vaccines in adults and children with asthma, and review 
articles. This process left 122 articles that required a more 
detailed evaluation, 92 of which did not fulfill the inclusion 
criteria. The number of studies that met all of the inclusion 
criteria was 30 (Figure 1).
Selection criteria
This review included RCTs, cohort studies, and case-con-
trol studies carried out in any country until the end of 
December 2011. Studies eligible for inclusion were those 
assessing any preparation of seasonal influenza vaccine, 
administered via any route to healthy participants up to 
and including the age of 18 years. For inclusion, studies 
had to have a comparison to a control group that received 
either an alternative vaccine, placebo, or no intervention. 
Outcome measures considered for inclusion were cases of 
influenza or ILI confirmed either clinically or by laboratory 
techniques, hospitalizations due to influenza, and preven-
tive efficacy or effectiveness of vaccines. For the purposes 
of this review, efficacy was defined as the ability of the vac-
cine to reduce the number of laboratory-confirmed cases 
of illness caused by influenza infection. Effectiveness was 
defined as the ability of the vaccine to reduce clinical cases 
of symptomatic influenza-like illnesses.
We excluded the studies that assessed vaccines in children 
with chronic illnesses, such as asthma. Searches also pro-
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duced a considerable number of studies that did not re-
cord clinical outcomes, but rather defined the presence 
of infection using serological data, such as antibody titers. 
Those studies were also excluded from the assessment of 
effectiveness.
Data analysis
We extracted information on the main characteristics of the 
studies on live vaccines (Table 1) and inactivated vaccines 
(Table 2) for all 30 studies. In order to judge the quality of 
the studies, further information about randomization, allo-
cation concealment, intention to treat analysis, and blind-
ing was extracted. We assessed the quality of studies using 
standard GRADE criteria (Supplementary Table S1) and ex-
tracted detailed definitions on the outcomes used in the 
studies (Supplementary Table S2). Potential confounding 
factors and any resulting adjustments were also recorded. 
In the studies that reported overall vaccine efficacy or ef-
fectiveness (VE), calculating it as:
VE = 100% - odds ratio (OR); or VE = 100% - risk ratio (RR),
with 95% confidence intervals (CIs) provided, results were 
entered directly into the data extraction table. Wherever 
studies had reported OR or RR, the overall VE and CIs were 
calculated. In the studies that only reported the number of 
ILIs (or laboratory-confirmed influenza cases) in vaccinated 
individuals and controls, the OR was calculated and overall 
VE and CIs recorded. Studies were then classified by out-
comes, to allow separate assessment of efficacy and effec-
tiveness. Tables were created to compare the efficacy or ef-
fectiveness of live and inactivated vaccines (Table 3-6). From 
each table, the data were used to perform 7 separate meta-
analyses: for efficacy of live vaccines (based on similar anti-
gen and per protocol analysis, similar antigen and intention 
to treat analysis, any antigen and per protocol analysis, and 
any antigen and intention to treat analysis), efficacy of inac-
tivated vaccines (based on similar antigen, any analysis), ef-
fectiveness of live vaccines, and effectiveness of inactivated 
vaccines (supplementary Figures S1-S7). Two results were 
reported for each meta-analysis, based on random effects 
model and fixed effects model, and presenting pooled me-
ta-estimates with 95% confidence intervals. For all computa-
tions, Stata 11.2 (StataCorp, TX, USA) was used.
FIguRe 1. A summary of the literature review.
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ReSuLtS
The retained 30 studies comprised 19 RCTs (10-28), 9 co-
hort studies (29-37), and 2 case-control studies (38,39). There 
were 9 studies that assessed the efficacy of live vaccines, 8 of 
which were RCTs (11-14,20,22,26,27) and 1 was cohort study 
(31). Eight studies evaluated the effectiveness of live vaccines: 
4 RCTs (10,19,24,25) and 4 cohort studies (30,31,34,35). Thir-
teen studies assessed the efficacy of inactivated vaccines: 7 
RCTs (13,14,16-18,21,28), 4 cohort studies (32,33,36,37), and 2 
case-control studies (38,39). Eight studies assessed the effec-
tiveness of inactivated vaccines: 5 RCTs (15-17,23,24) and 3 
cohort studies (29,32,36). The results were expected to show 
higher efficacy (which was assessed against proven influen-
za infection) than effectiveness (which would be measured 
against any cause of respiratory illness).
tAbLe 1. Characteristics of studies on live vaccines
Author (year of 
publi-cation) Location
Age of study 
population
Study 
design type of vaccine
Alexandrova 
(1986)
USSR 3-15 years RCT Live cold-adapted recombinant bivalent vaccine of influenza A 47/25/1 (H1N1) 
and 47/7/2 (H3N2).
Belshe (1998) USA 15-71 months RCT Live attenuated cold-adapted trivalent vaccine containing influenza A/
Texas/36/91-like (H1N1), A/Wuhan/359/95-like (H3N2) and B/Harbin/7/94-like 
viruses.
Belshe (2000) USA 26-85 months RCT Live attenuated cold-adapted trivalent vaccine containing influenza A/
Shenzhen/227/95-like (H1N1),
A/Wuhan/359/95 (H3N2) and B/Harbin/94-like viruses.
Beutner (1979) USA 7-14 years RCT Live recombinant influenza vaccine (X-42)
Clover (1991) USA 3-18 years RCT Live attenuated bivalent cold recombinant vaccine containing A/Bethesda/1/85 
(H3N2) and A/Texas/1/85 (H1N1).
Khan (1996) Russia 9-12 years RCT Live, trivalent attenuated, cold-adapted vaccine containing A/Leningrad/92/89 
(H1N1), A/Zakarpatje/354/89 (H3N2) and B/Yamagata/16/88
Longini (2000) USA 15-71 months RCT Live attenuated, cold-adapted influenza vaccine. The vaccine attenuated strains 
were matched to the antigens as recommended for the trivalent inactivated 
influenza vaccines by the Food and Drug Admini-stration for the 1996-97 and 
1997-98 influenza seasons
Neto (2009) South Africa, 
Brazil, 
Argentina
6 to <36 
months
RCT Live attenuated influenza vaccine, containing reassortant influenza virus strains 
containing the haemagglutinin and neuraminidase antigens of influenza virus 
strains recommended by the WHO
Rudenko (1993) Russia, 
Novgorod
7-14 years RCT Live attenuated vaccine containing, in 1989: A/Taiwan/1/86 (H1N1)-like, 
A/Sichuan/2/87 (H3N2)-like and in 1990: A/Taiwan/1/86 (H1N1)-like, A/
Shanghai/11/87 (H3N2) and B/Victoria/2/87-like.
Rudenko (1996) Russia, Cuba 3-15 years RCT Live, cold-adapted influenza vaccine. (No further details provided).
Tam (2007) South East 
Asia
12 to <36 
months
RCT Live CAIV-T, in year 1: A/New Caledonia/20/99 (H1N1), A/Sydney/05/97 (H3N2) and 
B/Yamanashi/ 166/98 and in year 2: A/New Caledonia/20/99, A/Panama/2007/99 
and B/Yamanashi/166/98. Composition was planned to be antigenically represen-
tative of the WHO recommendations for the Northern hemisphere each year.
Vesikari (2006) Europe 6 to <36 
months
RCT Live CAIV-T containing in year 1: A/New Caledonia/20/99 (H1N1), A/Sydney/05/97 
(H3N2) and B/Yamanashi/166/98 and in year 2: A/New Caledonia/ 20/99, A/
Panama/2007/99 and B/Victoria/504/2000.
Gaglani (2004) USA 1.5-18 years Cohort 
study
Live, attenuated, cold-adapted influenza vaccine containing A/Beijing/262/95 
(H1N1) [A/New Caledonia/20/99 (H1N1) in 2000], A/Sydney/05/97 (H3N2) and B/
Beijing/184/93-like strains.
Halloran (2003) USA 1.5-18 years Cohort 
study
Live-attenuated, trivalent, cold-adapted vaccine containing strains A/
Beijing/262/95 (H1N1) [A/New Caledonia/20/99 (H1N1) in 2001], A/Sydney/5/97 
(H3N2) and B/Beijing/184/93-like.
Piedra (2005) USA 1.5-18 years Cohort 
study
Live trivalent attenuated vaccine (CAIV-T) containing, in 1998-99: A/
Beijing/262/95 (H1N1) [A/Caledonia/20/99 in 2000-01], A/Sydney/05/97 (H3N2) 
and B/Beijing/184/93-like.
Piedra (2007) USA 5-18 years Cohort 
study
Live trivalent attenuated influenza vaccine containing A/New Caledonia/20/99 
(H1N1)-like, A/Panama/2007/99 (H3N2)-like, B/Hong Kong/330/2001-like
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Assessment of quality of the evidence
To assess the quality of studies we used the GRADE criteria 
(40) (supplementary material). In terms of study design, 19 
RCTs were used along with 11 observational studies (9 co-
hort and 2 case-control). Observational studies, in gener-
al, have lower validity than RCTs, and overall study quality 
was moderate. Results for the efficacy of inactivated vac-
cines were not particularly consistent, which may partly be 
due to strain matching of vaccines to viruses. Directness of 
the studies was good, with age groups, interventions used, 
and definition of outcomes all showing the expected di-
rectness when compared to the final outcomes. The het-
erogeneity of ILI definitions weakened directness slightly.
efficacy of live and inactivated vaccines
Vaccine efficacy for live vaccines, using random effects 
model, was as follows: (i) for similar antigen, using per-pro-
tocol analysis: 83.4% (78.3%-88.8%); (ii) for similar antigen, 
tAbLe 2. Characteristics of studies on inactivated vaccines
Author (year of 
publication) Location
Age of study 
population
Study 
design type of vaccine
Beutner (1979) USA 7-14 years RCT Inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (X-41).
Clover (1991) USA 3-18 years RCT Inactivated trivalent vaccine containing A/Chile/83 (H1N1), A/Mississippi/85 
(H3N2) and B/Ann Arbor/86
Colombo (2001) Italy 1-6 years RCT Inactivated trivalent subvirion vaccine containing A/Johannesburg/33/94-like, A/
Singapore/6/86-like and B/Beijing/184/93-like.
Cowling (2010) Hong Kong, 
Kowloon
6-15 years RCT Inactivated TIV seasonal vaccine containing strains A/Brisbane/59/2007 (H1N1)-
like, A/Brisbane/10/2007(H3N2)-like and B/Florida/4/2006.
Gruber (1990) USA 3-18 years RCT Inactivated TIV containing A/Chile/83 (H1N1), A/Philippines/82 (H3N2) and B/
USSR/83 strains.
Hoberman (2003) USA 6-24 months RCT Inactivated trivalent subvirion influenza vaccine in 1999-200, containing: A/
Beijing/262/95 (H1N1), A/Sydney/15/97 (H3N2) and B/Yamanashi/166/98 and 
in 2000-01: A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/
Yamanashi/166/98
Khan (1996) Russia 9-12 years RCT Inactivated, trivalent split-virus influenza vaccine containing A/Taiwan/1/86 
(H1N1), A/Shanghai/16/89 (H3N2) and B/Yamagata/16/88
Maeda (2004) Japan 6-24 months RCT Inactivated influenza vaccine containing, in 1999-2000: A/Beijing/262/95 
H1N1), A/Sydney/5/97 (H3N2) and B/Shandong/7/97. In 2000-01: A/New 
Caledonia/20/99, A/Panama/2007/99 and B/Johannesburg/5/99. In 2001-02: A/
New Caledonia/20/99, A/Panama/2007/99 and B/Johannesburg/5/99
Principi (2003) Italy 0.5-5 years RCT Inactivated virosomal influenza vaccine (no information on strains included)
Rudenko (1993) Russia 7-14 years RCT Inactivated (strains contained are the same as in the live vaccine, detailed 
above).
Vesikari (2011) Germany, 
Finland
6 to <72 
months
RCT Inactivated, TIV containing, in 2007-08: A/Solomon Islands/3/2006 (H1N1), A/
Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 and in 2008-09: A/
Brisbane/59/2007, A/Brisbane/10/2007 and B/Florida/4/2006 and TIV MF59 emul-
sion adjuvant
Fujieda (2008) Japan Under 6 years Cohort 
study
Inactivated TIV containing A/New Caledonia/20/99 (H1N1), A/
Panama/2007/99(H3N2) and B/Shandong/7/97.
Heikkinen (1991) Finland 1-3 years Cohort 
study
Inactivated, trivalent subvirion influenza vaccine containing A/Taiwan/1/86 
(H1N1), A/Sichuan/2/87 (H3N2) and B/Victoria/2/87.
Katayose (2011) Japan 0.5-5 years Cohort 
study
Inactivated TIV - vaccine components were decided yearly, by National Institute 
of Infectious Diseases, Japan based on WHO recommendations
Salleras (2006) Spain 3-14 years Cohort 
study
Inactivated virosomal subunit influenza vaccine (no further details)
Yamaguchi (2010) Japan 6-12 years Cohort 
study
Inactivated trivalent influenza vaccine containing A/New Caledonia/20/99 
(H1N1), A/Hiroshima/52/2005 (H3N2) and B/Malaysia/2506/2004
Joshi (2009) USA 6-59 months Case-
control
Inactivated trivalent influenza vaccine strains contained over the 8-year study 
period varied according to ACIP recommendations
Kelly (2011) Australia, 
Western 
Australia
0.5-5 years Case-
control
Inactivated trivalent influenza vaccine containing A/Solomon Islands/3/2006 
(H1N1)-like strain, an A/Brisbane/10/2007 (H3N2)-like strain and B/
Florida/4/2006-like strain
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using intention to treat analysis: 82.5 (76.7%-88.6%); (iii) 
for any antigen, using per protocol analysis: 76.4% (68.7%-
85.0%); (iv) for any antigen, using intention to treat analysis: 
76.7% (68.8%-85.6%). Vaccine efficacy for inactivated vac-
cines, for similar antigen, using random effects model, was 
67.3% (58.2%-77.9%). The results of fixed-effects model con-
sistently showed slightly greater efficacy than the results of 
random-effects model (Supplementary Figure S1-S5).
One study (33) recorded the efficacy of inactivated vac-
cines in children up to 6 years old only, and presented the 
results by age group. The efficacy was consistently high in 
the 6 months to 1 year age group. Only one study (28) as-
sessed the efficacy of an adjuvanted inactivated vaccine 
and compared it to a non-adjuvanted inactivated vaccine. 
The adjuvanted vaccine showed a greater efficacy than 
control and also non-adjuvanted vaccine. The efficacy of 
the adjuvanted vaccine in this study was 80%, which is 
comparable to the efficacy of live vaccines. The effect of 
inactivated vaccines on reducing hospitalization was only 
recorded in one study (33), which showed the overall effi-
cacy of 71% in reducing hospitalizations from influenza A 
infection in children aged 6 months to 6 years and of 72% 
for influenza B infection.
effectiveness of live and inactivated vaccines
Vaccine effectiveness against influenza-like illness for live 
vaccines, using random effects model, was 31.4% (24.8%-
39.6%) and using fixed-effect model 44.3% (42.6%-45.9%). 
Vaccine effectiveness against influenza-like illness for inac-
tivated vaccines, using random effects model, was 32.5% 
(20.0%-52.9%) and 42.6% (38.3%-47.5%) using fixed-effect 
model (Supplementary Figure S6-S7). Clearly, the lower 
values for effectiveness than for efficacy reflect the differ-
ences in outcomes used in the studies. The estimates of ef-
ficacy were based on studying the outcomes which influ-
enza vaccines were designed to protect against, while for 
assessing effectiveness the outcomes were less specific.
DISCuSSIoN
This review showed a high efficacy of influenza vaccines 
against influenza infection, but a considerably lower effec-
tAbLe 3. A review of efficacy estimates for live vaccines (PPt– per protocol; Itt – intention to treat).
Author 
(year of 
publication)
Study 
design
type of 
vaccine Control
Age of study 
population
overall vaccine 
efficacy (Ve)
Lower confidence 
interval limit (for 
overall Ve)
upper confidence 
interval limit (for 
overall Ve)
Belshe (1998) RCT Live Placebo 15-71 months 0.93 0.88 0.96
Belshe (2000) RCT Live Placebo 26-85 months 0.87 0.78 0.93
Beutner (1979) RCT Live Placebo 7-14 years 0.62 0.44 0.87
Clover (1991) RCT Live Placebo 3-18 years 0.65 0.31 1.36
Longini (2000) RCT Live Placebo 15-71 months 1996-97: 0.90
1997-98: 0.85
0.51
0.47
1.59
1.53
Neto (2009) RCT Live Placebo 6 to <36 months Year 1, similar antigen: 0.74
Year 1, any antigen: 0.72
Year 2, similar antigen: 0.74
Year 2, any antigen: 0.47
0.64
0.62
0.33
0.15
0.81
0.80
0.91
0.67
Tam (2007) RCT Live Placebo 12 to <36 months Year 1, PPT, similar antigen: 0.73
Year 1, PPT, any antigen: 0.70
Year 1, ITT, similar antigen: 0.70
Year 1, ITT, any antigen: 0.68
Year 2, PPT, similar antigen: 0.84
Year 2, PPT, any antigen: 0.64
0.63
0.61
0.60
0.59
0.70
0.44
0.81
0.77
0.78
0.75
0.92
0.77
Vesikari (2006) RCT Live Placebo 6 to <36 months Year 1, PPT, similar antigen: 0.85
Year 1, PPT, any antigen: 0.86
Year 1, ITT, similar antigen: 0.84
Year 1, ITT, any antigen: 0.84
Year 2, PPT, similar antigen: 0.89
Year 2, PPT, any antigen: 0.86
Year 2, ITT, similar antigen: 0.89
Year 2, ITT, any antigen: 0.85
0.74
0.76
0.73
0.74
0.82
0.79
0.83
0.78
0.92
0.92
0.91
0.90
0.93
0.91
0.93
0.90
Halloran (2003) Cohort 
study
Live No 
intervention
1.5-18 years Combined, A (H1N1) and B: 0.91 -0.34 0.99
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tiveness. There was a slight difference in favor of live vac-
cines in efficacy, but hardly any in effectiveness. Two studies 
demonstrated the efficacy of live vaccines in children under 
2 years of age (22,27), which was an important contribution 
to available information on this age group. Expectedly, both 
live and inactivated vaccines were more efficacious against 
infection with strains of influenza virus that were antigeni-
cally similar to strains contained in the vaccine (22,26-28), 
highlighting the need for good strain-matching for the vac-
cines that are being delivered in large programs. Adjuvant-
ed inactivated vaccines showed efficacy almost as good as 
that of live vaccines, although this result came from only one 
study (28). These conclusions are in line with previously con-
ducted systematic reviews on influenza vaccines (41), sug-
gesting that there is a growing agreement about the key 
technical indicators, and that the future research challenges 
will be more focused on achieving more equitable impact of 
the available preventive interventions (42).
tAbLe 4. A review of efficacy estimates for inactivated vaccines.
Author (year 
of publication)
Study 
design
type of 
vaccine Control
Age of study 
population
overall vaccine 
efficacy (Ve)
Lower confidence 
interval limit (for 
overall Ve)
upper confidence 
interval limit (for 
overall Ve)
Beutner (1979) RCT Inactivated Placebo 7-14 years 0.82 0.55 1.23
Clover (1991) RCT Inactivated Placebo 3-18 years 0.74 0.29 1.88
Cowling (2010) RCT Inactivated Placebo 6-15 years 0.56 0.25 1.23
Gruber (1990) RCT Inactivated Placebo 3-18 years Against influenza B: 0.75 0.34 1.64
Hoberman 
(2003)
RCT Inactivated Placebo 6-24 months 0.66 0.34 0.82
Maeda (2004) RCT Inactivated No intervention 6-24 months Against influenza A: 0.45 0.18 1.10
Vesikari (2011) RCT Inactivated Placebo 6 to <72 
months
Year 1, any antigen: 0.43
Year 1, similar antigen: 0.45
Year 2, any antigen: 0.40
Year 2, similar antigen: 0.41
0.15
0.16
-0.06
-0.89
0.61
0.64
0.66
0.58
Heikkinen 
(1991)
Cohort 
study
Inactivated No intervention 1-3 years Against influenza A: 0.85 0.32 2.24
Katayose (2011) Cohort 
study
Inactivated No intervention 0.5-5 years Against influenza A: 0.53 0.41 0.63
Salleras (2006) Cohort 
study
Inactivated No intervention 3-14 years Against influenza A: 0.88 0.49 0.97
Yamaguchi 
(2010)
Cohort 
study
Inactivated No intervention 6-12 years 0.82 0.60 1.12
Joshi (2009) Case-
control
Inactivated Negative laboratory 
test for influenza-like 
illness (ILI)
6-59 months 0.86 0.29 0.97
Kelly (2011) Case-
control
Inactivated Negative laboratory 
test for ILI
0.5-5 years 0.58 0.09 0.81
tAbLe 5. A review of effectiveness estimates for live vaccines
Author (year 
of publication)
Study 
design
type of 
vaccine Control
Age of study 
population
overall vaccine 
effectiveness
Lower confidence 
interval limit
upper confidence 
interval limit
Alexandrova (1986) RCT Live Placebo 3-15 years 0.55 0.51 0.60
Khan (1996) RCT Live Placebo 9-12 years 0.47 0.35 0.61
Rudenko (1993) RCT Live Placebo 7-14 years Year 1: 0.48
Year 2: 0.41
0.22
0.14
0.58
0.54
Rudenko (1996) RCT Live No intervention 3-15 years Year 1: 0.36
Year 2: 0.48
0.33
0.45
0.39
0.50
Gaglani (2004) Cohort study Live No intervention 1.5-18 years Year 1: 0.22
Year 2: 0.21
0.11
0.10
0.32
0.31
Halloran (2003) Cohort study Live No intervention 1.5-18 years 0.18 0.11 0.24
Piedra (2005) Cohort study Live Placebo 1.5-5 years 0.07 0.05 0.09
Piedra (2007) Cohort study Live No intervention 5-18 years 0.42 0.35 0.50
IMPROVING GLOBAL CHILD HEALTH 142 Croat Med J. 2013;54:135-45
www.cmj.hr
This report has several limitations. We performed meta-
analyses of the studies that were matched for the type of 
vaccine (live or inactivated), antigen used (similar or any), 
and analysis used (per protocol or intention to treat). Still, 
studies that were grouped together varied in study designs, 
case definitions, and age ranges applied (Supplementary 
material). Moreover, we excluded several papers in Russian 
(43-49), because it was not possible for us to assess full text 
articles and we already felt that we had enough evidence. 
For a more in depth review, we could also consider wider 
aspects of influenza vaccination, such as the cost-effective-
ness and safety of implementing vaccination programs for 
different age groups, the effect that vaccination may have 
on reducing absence from school and parents’ absence 
from work, and acceptability of vaccine to providers and 
end-users. There have been studies researching the indi-
rect beneficial effect that vaccinating children has on mor-
bidity and mortality from influenza in the elderly (9), which 
could be another interesting research area.
In many studies, there was a lack of information on the 
composition of the vaccine used and its matching to the 
circulating strains of influenza viruses for that season. This 
is vital as it inevitably will have a significant effect on the 
efficacy of vaccines. Influenza vaccines will not have ef-
fect against antigenically dissimilar viruses. There are also 
some limitations imposed by the nature of research avail-
able in the area of influenza vaccines. There were no stud-
ies that directly compared live and inactivated vaccines, 
although such studies would allow an analysis of the ef-
ficacy and effectiveness of the vaccines in a comparable 
context. There was a considerable heterogeneity in the 
outcome definitions used in the studies, particu-
larly with reference to ILI definitions. Studies also differed 
according to methods of collecting data on ILIs; in some 
studies cases were diagnosed by general practitioners or 
pediatricians on visits to a clinic and in others according to 
parental reports of symptoms.
The main strength of this review, compared to other rel-
evant literature, is that it summarized the available infor-
mation on this issue and provided an evidence base from 
which further research could be conducted. It exposed dif-
ferences in the quality and methodological approaches 
to studies, such as the definition of outcomes and study 
designs and gaps in information provided for certain age 
groups. It strengthened the existing knowledge, providing 
a summary of the data on the effect of live and inactivat-
ed vaccines in preventing influenza in children, in whom 
it showed comparable results to healthy adults. Areas for 
future research have also been highlighted, such as the di-
rect comparison of the efficacy of live and inactivated vac-
cines, more systematic research into benefits of each type 
of vaccine for different age groups, and the need for a wid-
er evidence base supporting potentially promising adju-
vanted inactivated influenza vaccines (50).
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